Alaska Airlines to Fly to Rome Next Year in Europe Debut
Based on what we saw during Alaska's investor day in December, expect more routes to Europe and Asia, including London, Paris, Bangkok, and Ho Chi Minh City.
Alaska Airlines announced Tuesday that it plans to fly from Seattle to Rome, marking the carrier's first route to Europe.
Flights will begin in May 2026 and go on sale this fall. Alaska said it would operate the route four times a week using a Boeing 787-9.
The new destination is part of Alaska's strategy to expand into the international market following its merger with Hawaiian Airlines. Through the merger, Alaska acquired Hawaiian's widebody fleet, which includes Boeing 787s and Airbus A330s.
In order to operate the route, Alaska needs approval from the Federal Aviation Administration to have its combined fleet from Hawaiian on a single operating certificate. Alaska said it expects to receive the approval in the fall.
Customers also have the opportunity to join an early-access list to be notified when flights can be purchased.
Alaska's International Ambitions
Italy is one of the most popular tourist destinations for Americans, and U.S. airlines have recently been adding more routes to the country. Both United Airlines and Delta Air Lines added routes to Sicily. American Airlines also expanded its schedule to Italy, increasing flights to Rome, Naples, and Venice.
Alaska said Rome is not currently served by a nonstop flight from Seattle, and the city was among the most-requested destinations for members of the carrier's loyalty program, MileagePlan.
The Seattle-based carrier had been eyeing a European expansion for some time. CEO Ben Minicucci said during a Wings Club event in New York in March that Europe was 'definitely on the radar for 2026.'
During Alaska's investor day in December, executives presented a map with multiple international destinations to Europe and Asia. That map included London, Paris, and Rome, along with Bangkok and Ho Chi Minh City.
In May, Alaska debuted flights from Seattle to Tokyo and plans to launch a route to Seoul in September.
What am I looking at? The performance of airline sector stocks within the ST200. The index includes companies publicly traded across global markets including network carriers, low-cost carriers, and other related companies.
The Skift Travel 200 (ST200) combines the financial performance of nearly 200 travel companies worth more than a trillion dollars into a single number. See more airlines sector financial performance.
Read the full methodology behind the Skift Travel 200.
Related
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
11 minutes ago
- Associated Press
Europe's central bank expected to lower interest rates as Trump's trade war threatens growth
FRANKFURT, Germany (AP) — Lower inflation and concern that U.S. President Donald Trump's trade war will slow already modest growth have cleared the way for the European Central Bank to cut interest rates at Thursday's policy meeting, a step that would lower borrowing costs for consumers and businesses and promote economic activity. With a cut widely expected by market analysts, a key question is how low the bank will go, given uncertainty about the impact of U.S. trade policy on Europe's export-dependent economy. Bank President Christine Lagarde will face questions about the bank's outlook for coming meetings at her post-decision news conference. A cut of a quarter percentage point would be the eighth rate cut since June 2024 and would take the bank's benchmark rate to 2%. Trump on April 2 announced a 20% tariff, or import tax, on goods from the European Union. He later threatened to raise the tariff to 50% after expressing dissatisfaction with the progress of trade talks with the EU. Trump and the EU's executive commission have agreed to suspend implementation and any retaliation by the EU until July 14 as negotiators seek to reach agreement. Trump added more disruption this week by suddenly increasing a 25% tariff on steel imports to 50% for all countries except for the U.K. The threat of even higher tariffs has raised fears that growth will underperform already modest forecasts. The EU's executive commission lowered its growth forecast for this year to 0.9% from 1.3% on the optimistic assumption that the 20% tariff rate can be negotiated down to no more than 10%. Low inflation has bolstered the ECB's ability to cut rates. Annual inflation for the 20 countries that use the euro fell to 1.9% in May from 2.2% in April as energy prices eased. The ECB raised rates to a record high of 4% to suppress a 2021-2023 inflation outbreak that reached double digits. But with inflation now below its 2% target, the bank has more freedom to cut. Lower rates make it cheaper to borrow and buy things, supporting demand for goods and in theory increasing spending and investment.
Medscape
14 minutes ago
- Medscape
New Hyperkalemia Risk Model for CKD and Diabetes
A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications like finerenone. However, researchers caution that further validation is needed. The model is based on pooled data from two phase 3 trials of finerenone: FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) and FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease). The combined dataset, known as FIDELITY, includes 6355 patients in the placebo groups. Researchers used this dataset to develop the risk score, identifying seven factors independently associated with the primary outcome of new onset of hyperkalemia (incident serum potassium level > 5.5 mmol/L): Serum potassium > 4.5 mmol/L Prior history of hyperkalemia No use of sodium-glucose co-transporter 2 inhibitor Urine albumin-to-creatinine ratio > 1000 mg/g Hemoglobin < 12 g/dL No use of thiazide-type diuretics Estimated glomerular filtration rate < 45 mL/min/1.73 m2 The model was subsequently validated using data from the finerenone groups in FIDELITY. In their paper, published online in the European Heart Journal , João Pedro Ferreira, MD, PhD, of the Cardiovascular Research and Development Center at the University of Porto, Porto, Portugal, and coauthors noted that the model could be used to reduce the risk for hyperkalemia among high-risk patients receiving finerenone. 'This could include tailoring of individualized treatment and follow-up strategies (eg, frequency of visits and serum potassium assessments, and use of potassium binders), thus optimizing patient management and potentially improving outcomes,' they noted. Welcome Results, Validation Required CKD, which affects more than 800 million people worldwide, is a common complication of diabetes. An estimated 15%-40% of people with CKD in the setting of diabetes may have hyperkalemia, noted Bernard G. Jaar, MD, MPH, clinical director for Nephrology at Johns Hopkins School of Medicine, Baltimore, who was not involved in the study. In an email exchange with Medscape Medical News , Jaar described the study as 'welcome and much needed.' He noted that hyperkalemia poses a challenge for clinicians, as many medications required for optimal care in CKD — including renin-angiotensin-aldosterone system (RAAS) blockade agents and finerenone — can raise serum potassium. 'This is a true barrier to care,' Jaar wrote. 'Clinicians are worried about the potential complications associated with hyperkalemia, such as arrhythmias and even death.' Jaar noted that the FIDELITY analysis has several strengths, including its large sample size of patients with varying stages of CKD and degrees of proteinuria, and a risk score model that incorporated readily available clinical variables. He added that it reports a stepwise increase in hyperkalemia risk across risk score tertiles in both placebo and finerenone groups, even though all patients were already on a maximally tolerated RAAS blockade agent. However, he questioned the study's generalizability, given that it excluded patients if their serum potassium was > 4.8 mmol/L. 'This risk model in predicting hyperkalemia needs to be validated in other populations where diet may be different,' Jaar wrote. 'Also, this needs to be validated in at-risk populations during real-life experience and not only in patients enrolled in clinical trials, who are typically highly motivated and selected.' Future Applications Rajiv Agarwal, MD, MS, professor emeritus of medicine at Indiana University and a lead researcher in the finerenone clinical studies, echoed the need for further validation of this tool. Although not involved with the development of the risk model, Agarwal was an author on key publications from the FIGARO-DKD, FIDELIO-DKD, and FIDELITY studies. Agarwal suggested that this model's approach could be applied to other therapies, including aldosterone synthase inhibitors in a similar population with CKD. He also noted the importance of incorporating validated risk models for hyperkalemia into electronic medical records or apps, particularly in countries with limited access to care, like China and India. This would allow more nuanced approaches for following up patients taking drugs with established hyperkalemia risk. 'If the patient cannot come after a month, can I make a clinical judgment and say, 'Okay, if you came back after 3 months, your risk of hyperkalemia is low enough that I'm willing to take that risk,'' he said. 'Or if the risk of hyperkalemia is high, you can tell the patient who can't come back in 30 days, 'I don't think I want to prescribe this drug for you'.' The work on the risk model was supported by Bayer, which also funded the FIDELIO-DKD and FIGARO-DKD studies and pooled analysis. The study's authors included Bayer employees. Other financial relationships of the authors included research support, consulting and other fees from companies including: Abbott Vascular, Amgen, Astellas, AstraZeneca, Bayer, BioVentrix, Boehringer Ingelheim, Brahms, Brainstorm Medical, Cardiac Dimensions, Cardior, Cereno Scientific, CSL Vifor, CVRx, Edwards, Eli Lilly, G3 Pharmaceuticals, Gilead, GSK, Impulse Dynamics, Janssen, KBP Biosciences, Mundipharma, Novartis, Novo Nordisk, Occlutech, PhaseBio, Proton Intel, Respicardia, Sanofi, Sarfez, scPharmaceuticals, Servier, SQ Innovation, Tricida, Vectorious, Vifor International, and V-Wave. Agarwal had received support from Bayer. He also had received consulting fees and other support from Boehringer Ingelheim, Novartis, Akebia, Intercept Pharma, Alnylam, and Vertex. Jaar reported no relevant financial disclosures.
Forbes
31 minutes ago
- Forbes
Retiring Retirement: Rethinking Growth In The Age Of Longevity
Preparing For The Marathon Of Longer Lives At UniCredit's 2025 Longevity Economic Forum in Milan, the central question wasn't whether people will live longer—they already are. It was how we build lives, markets, and meaning around that fact. The number of conferences on longevity is fast multiplying, but this was one of the first hosted by a leading financial institution and focusing on the economic implications of our new demographic era. In a world where people increasingly live into their 90s and beyond, traditional assumptions about retirement, careers, and consumer behaviour are no longer viable. Yet few institutions—whether governmental, financial, or social—have adapted. And we lack the metrics to evaluate where countries are on the journey to longevity readiness. For the moment, says NICA's Nic Palmarini, they are all over the map. From Nic Palmarini of the UK National Innovation Center for Ageing (NICA) The three organisations hosting the conference (Unicredit, Fidelity and the UK National Innovation Center on Ageing, or NICA) announced the launch of two new tools to start measuring progress. One looks at systems, the other at lives. Together, they reveal the conditions needed to foster healthy, empowered ageing. I'll cover the results of each in subsequent articles. The Wakeup Call From the OECD The OECD's Stefano Scarpetto gave the wake up call on the demographic context. Populations are living longer while fertility rates are plummeting. Economies will begin to shrink drastically as populations age out of work. There are three unavoidable levers to address the shortfall, he said: Two Nobel Laureates helped frame the conversation. Economist Robert Merton, known for his work on retirement finance, argued that the goal isn't accumulated wealth, but an inflation-protected income that preserves one's standard of living. He proposed a six-part framework for funding retirement that includes innovative tools like Retirement Security Bonds. Now being rolled out in Brazil. Robert Merton's 6 Pillars Of Retirement Financing Fellow laureate Michael Spence, at 81 competing with his 80-year-old colleague on both age and wisdom, emphasised that inclusive growth and productivity will hinge on how societies tap into the capacities of older adults. If we fail to reinvent retirement, and address the dramatic inequality and diversity among ageing populations, we risk expanding lifespan without improving life quality – or productivity. Three panels looked at how these ideas are being put into action - and where. The first focused on new forms of investment and flexing rhythms of accumulation and decumulation. The second on how lifestyles are evolving and the companies serving these new and emerging needs, and the last debated how to insure and protect people across multiplying life stages. The first panel explored how financial institutions and investors can recalibrate for century-long lifespans. Experts from Fidelity, PGGM, and Unicredit discussed the need for longer investment horizons, more adaptive pension systems, and better design around intergenerational wealth transfers. A standout theme was the reframing of longevity as a market opportunity. Healthtech, housing, and digital wellness emerged as growth sectors. Technogym's Erica Alessandri underscored the value of fitness as a preventive corporate competitiveness asset, dramatically improving the health of employees. Real estate company Hines' Mario Abbadessa said that senior living was no longer a niche market, but has become his company's core business. Fiona Melrose of UniCredit argued that longevity-conscious banking—offering tools for wellness, planning, and resilience—should be a part of every ESG strategy. Katie Hart, a neuromarketer, said we can now physiologically measure how older consumers think, feel, and choose differently through brain scans. It's not, she suggests 'about decline but about understanding difference.' Older brains exhibit slower decision speed, higher emotional processing, and a greater aversion to risk. They may be more attracted to 'wisdom than innovation.' And by 2030, the 60+ will control 70% of financial assets. Designing for them is also fast becoming central to good business. The final panel focused on resilience—across health, wealth, and care. Allianz's Arne Holzhausen outlined next-generation insurance products that combine financial protection with health data and digital tools. Humanitas presented their vision of healthcare moving from crisis to prevention, with clinics acting as local anchors for proactive, digitally supported care. But it was Annie Coleman's intervention that brought the human side of the longevity revolution into focus. Her call to move from retirement to 're-inspirement'—a reinvention of purpose, vitality, and contribution in later life—resonated with many. Her framework—productivity, vitality, transformation—offers a roadmap based on the Stanford Longevity Centre's new roadmap of life, designed to live our bonus decades with agency and joy. Longevity is no longer a niche topic. It's the defining growth opportunity of our age. But it requires a full-system rethink—from investment portfolios to health systems, from workplace design to social contracts. Claudia Parzani, Conference Host, Chair of the Italian Stock Exchange The UniCredit Longevity Economic Forum made one thing clear: the future isn't about debating dry demographic trends—it's about unlocking the full potential and productivity of our second halves. Everywhere.
